Lurbinectedin is a chemotherapy drug used for the treatment of certain types of cancer, including small cell lung cancer and metastatic triple-negative breast cancer. However, prolonged use of lurbinectedin may lead to several risks.

One of the main risks associated with lurbinectedin use is bone marrow suppression, which can cause a decrease in the number of red blood cells, white blood cells, and platelets in the body. This can lead to anemia, infections, and bleeding disorders [2]. Additionally, the use of lurbinectedin has been associated with liver toxicity, which can cause liver damage and liver function abnormalities [1].

Another risk of prolonged lurbinectedin use is cardiotoxicity, which can lead to heart damage and heart function abnormalities. This risk is particularly relevant for patients with pre-existing heart conditions or those who are receiving other medications that can cause heart damage [3].

Lurbinectedin may also cause gastrointestinal side effects, including nausea, vomiting, diarrhea, and abdominal pain. These side effects may be more severe with prolonged use of the drug [2].

In conclusion, while lurbinectedin is an effective chemotherapy drug for the treatment of certain types of cancer, it is not without risks. Prolonged use of the drug may lead to bone marrow suppression, liver toxicity, cardiotoxicity, and gastrointestinal side effects. Patients receiving lurbinectedin should be closely monitored for these potential side effects [1][2][3].

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://link.springer.com/article/10.1007/s00262-020-02513-y
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8972734/